AKANDA CORP.
AKANAbout the company
Akanda Corp., through its subsidiaries, operates as early-stage cannabis company in Mexico. It is involved in medical cannabis cultivation, manufacturing, and sale; and leasing and/or rental of fiber optic networks and telecommunication towers. The company is based in Toronto, Canada.
Investment snapshot
Positive
2
BUY / PASS
Neutral / negative
2 / 12
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | Not ranked | NEUTRAL | FAIL | PASS | FAIL | FAIL | FAIL | FAIL | PASS | FAIL | FAIL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | Annual history · FY 2024 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 · Market data at 2026-11-01 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2024 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2024 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 · Market data at 2026-11-01 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 · Qualitative assessment Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 Latest source filing: 2025-04-30 Score computed: 2026-11-14 | Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 Latest source filing: 2025-04-30 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 8✗ 20▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio0.7x✓Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-4220.5%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-4220.5%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per Share0.7x✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-217.4%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-169.3%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=0.7x✓MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low217% of trailing low ($0.63)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-114.11%; #5454/6340 (top 86.0%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+1.1913; #1207/6449 (top 18.7%)✓AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share0.65x✓SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.2331; #3626/5247 (top 69.1%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-169.33%; #4178/4519 (top 92.5%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date+117.25%; #276/6202 (top 4.5%)✓OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy$-4.9M✗BuffettPositive and growingFCF Positive and Growing$-6.1M✗LynchPositive and growingOperating Cash Flow$-4.0M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-50.29%, ROA=-51.76%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-169.3%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/4 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-218.3%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/4 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-6.1M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-169.33%; #4178/4519 (top 92.5%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 1✗ 12▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue Growth✗LynchInventory growth < Revenue growthEPS Growth Direction$-0.11 (2019) -> $-3.93 (2024)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/6 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth97.5%✓Ackman>= 5%Positive EPS Growth Frequency2/5 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 124.8% -> 24.9%, operating margin -770.2% -> -523.8%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Profitability6% pass✓ 6✗ 29▾
15 of 16 flag AKAN's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)0/7 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthNet Income Positive (10+ years)0/7 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-69.6%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-523.8% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-4.9M✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-95.8%✗Lynch> 15%EBIT / Enterprise Value-4220.5%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-4220.5%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-51.76%✗PiotroskiROA > 0ROA Change YoY-365.10% -> -51.76% (delta: +313.35%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-50.29%, ROA=-51.76%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY14.0% -> 24.9%✓PiotroskiImproved YoYPre-Tax Income / Revenue✗Dreman>= 8%Net Income / Shareholders' Equity-95.8%✗Dreman> 12%Margin of SafetyP/B=0.7x✓PabraiP/B < 1.5 or P/E < 15Return on Equity-69.6% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/6 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-523.8%✗Ackman>= 15%Net Income / Shareholders Equity-95.8%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-770.2% (2022) -> -523.8% (2024)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 124.8% -> 24.9%, operating margin -770.2% -> -523.8%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-114.11%; #5454/6340 (top 86.0%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+2.63%; #3232/3702 (top 87.3%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-95.78%; #4578/5226 (top 87.6%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-1.2457; #5337/5884 (top 90.7%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/6 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Efficiency13% pass✓ 2✗ 9▾
7 of 8 flag AKAN's efficiency — Graham, Buffett, Greenblatt +4 more
Current Ratio1.39✗Graham>= 2.0ROIC (3-5 yr avg)-239.9%✗Buffett> 10%ROIC - WACC-249.9%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)✗Greenblatt> 25%Current Ratio Change YoY0.18 -> 1.39✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.05x -> 0.11x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities1.39✗Dreman> 1.5Return on Invested Capital-74.8%✗Munger> 15%ROIC (high and growing)FY2022: ROIC=-52.3%; FY2023: ROIC=-8363.1%; FY2024: ROIC=-74.8%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/4 years above 12% (latest -74.8%)✗SleepROIC > 12% in a majority of years - Verdicts14% pass✓ 2✗ 12▾
Split decision: 12 FAIL · 2 NEUTRAL · 2 PASS
Overall verdict✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)•GreenblattNot ranked•PiotroskiNEUTRAL (F-Score 7)✗DremanFAIL (2/11)✓MungerPASS (2/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✗AckmanFAIL (3/9)✓TempletonPASS (4/8)✗SleepFAIL (0/6)✗AsnessFAIL (Rank #2283/2370 (Top 96.3%))✗NeffFAIL (1/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked) - Debt & Leverage50% pass✓ 9✗ 6▾
6 of 12 pass — Graham, Buffett, Lynch +3 more object
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.08, IC: -43.8x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0.08✓Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change28.25% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities1.39✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity0.08✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xDebt Levels0.08✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-43.8x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0.08✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.0825; #1195/4210 (top 28.4%)✓AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
| Metric | FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
| FY 2020Sources
|
|---|---|---|---|---|---|
| Market Cap | $3.6Mcurrent | $2.7Best. | $136.4Best. | $1.6Test. | -- |
| Revenue | $836.7K↑97% | $423.7K↓84% | $2.6M↑6223% | $41.4K↑1909% | $2.1K |
| Operating Income | -$4.4M↓20% | -$3.7M↑82% | -$20.2M↓685% | -$2.6M↓54% | -$1.7M |
| Net Income | -$4.1M↑87% | -$32.3M↓177% | -$11.7M↓43% | -$8.1M↓253% | -$2.3M |
| EPS (Diluted) | $-3.93↑45% | $-7.16↓1736% | $-0.39↑22% | $-0.50↓178% | $-0.18 |
| Gross Margin | 24.9%↑78% | 14.0%↓89% | 124.8%↑3350% | -3.8%↑100% | -2821.3% |
| Operating Margin | -523.8%↑39% | -863.6%↓12% | -770.2%↑88% | -6203.4%↑92% | -80781.0% |
| ROE | -95.8%↓111% | 842.9%↑2045% | -43.3%↓112% | 369.4%↑708% | 45.7% |
| Total Debt | $352.8K↓91% | $3.9M↑8% | $3.6M↓46% | $6.6M↑128% | $2.9M |
| Shareholders' Equity | $4.3M↑212% | -$3.8M↓114% | $26.9M↑1322% | -$2.2M↑56% | -$5.0M |
| Current Ratio | 1.39↑683% | 0.18↓57% | 0.41↓15% | 0.48↑930% | 0.05 |
| Debt / Equity | 0.08↑108% | -1.01↓861% | 0.13↑104% | -2.99↓422% | -0.57 |
| Operating Cash Flow | -$4.0M↓165% | -$1.5M↑87% | -$11.5M↓75% | -$6.6M | -- |
| Free Cash Flow | -$6.1M↓305% | -$1.5M↑87% | -$11.8M↓65% | -$7.1M | -- |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Pharmaceutical Products
AKAN vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc.MRK | $364.3B | $147.76 | $65.0B | $18.3B | 34.7% | 0.94 | — | 1.54 | 2/9 | 5/9 | 4/7 | 0/3 | F-Score 4 | 1/11 |
| ABBOTT LABORATORIESABT | $188.0B | $108.52 | $44.3B | $6.5B | 12.5% | 0.25 | 18.2% | 1.58 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 3/11 |
| BRISTOL MYERS SQUIBB COBMY | $129.7B | $63.43 | $48.2B | $7.1B | 38.2% | 2.44 | 19.4% | 1.26 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |
| BIO-TECHNE CorpTECH | $11.4B | $72.80 | $1.2B | $73.4M | 3.8% | — | 8.4% | 3.46 | 4/9 | 3/9 | 3/7 | 0/3 | F-Score 5 | 4/11 |
| REPLIGEN CORPRGEN | $10.7B | $167.79 | $738.3M | $48.9M | 2.3% | 0.26 | 7.5% | 8.37 | 3/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 5/11 |
| IONIS PHARMACEUTICALS INCIONS | $4.8B | $29.06 | $943.7M | $381.4M | -78.0% | 3.60 | -40.4% | 3.83 | 3/9 | 1/9 | 1/7 | 0/3 | F-Score 4 | 3/11 |
| NEOGEN CORPNEOG | $2.5B | $11.23 | $870.4M | $7.9M | -0.4% | 0.76 | -2.5% | 3.82 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 6 | 4/11 |
| Pharvaris N.V.PHVS | $2.4B | $33.36 | — | $206.4M | -64.8% | 0.00 | — | — | 0/9 | 0/9 | 2/7 | 0/3 | F-Score 2 | 2/11 |